ClinicalTrials.gg
CompletedNCT01482962Updated Jul 31, 2018Results posted

Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

A Phase 3 interventional study of Alisertib and Pralatrexate in Relapsed Peripheral T-Cell Lymphoma and Refractory Peripheral T-Cell Lymphoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 152 sites in 31 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-31.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
271
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 164 studies in Lymphoma, T-Cell, Peripheral with a site in United States — 21 open to participants now, 28 under way, 2 of them phase 3. Lymphoma, T-Cell, Peripheral · United States.

Enrollment
4th of 157
271 · median 36
Started
2012
with 8 others
Phase 3
5 of 164
1 open now
Registered
65th of 164
by date

Among the 164 studies in Lymphoma, T-Cell, Peripheral with a site in United States, this one is the 4th largest by enrollment of the 157 interventional ones that give a count, is one of 9 that started in 2012, is one of 5 in phase 3, and was the 65th registered.

Lymphoma, T-Cell, Peripheral

372 studies on the registry are indexed under Lymphoma, T-Cell, Peripheral; 110 are open to participants now.

Browse Lymphoma, T-Cell, Peripheral studies →

Open to participants now

21 of the 164 studies in Lymphoma, T-Cell, Peripheral with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 76 Lymphoma, T-Cell, Peripheral studies recruiting now, 30 (39%) set no upper age limit and 38 (50%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 164 studies in Lymphoma, T-Cell, Peripheral with a site in United States, or all of them as a file.
02

Study summary

This is a phase 3, randomized, 2-arm, open-label, international trial evaluating alisertib compared with single-agent treatment, as selected by the investigator from the offered options of pralatrexate or gemcitabine or romidepsin, in participants with relapsed or refractory peripheral T-cell lymphoma (PTCL). Note: romidepsin was not used as a single-agent comparator outside the United States of America (USA) as supply was not available.

Read the detailed description

The drug being tested in this study was Alisertib. Alisertib was tested to treat people who have relapsed/refractory peripheral T-cell lymphoma (PTCL).

This study evaluated alisertib for the improvement in overall response rate (ORR) compared with single-agent treatment, as selected by the investigator from the offered options of pralatrexate, romidepsin (US only), or gemcitabine, in participants with relapsed or refractory PTCL.

The study enrolled 271 patients. Participants were randomized (1:1) to one of 2 treatment arms:

  • Alisertib
  • Investigator's choice (Pralatrexate, Romidepsin, or Gemcitabine)

This multi-center trial was conducted worldwide. The overall time to participate in this study was approximately 5 years. Participants made multiple visits to the clinic, and then were contacted by telephone up to 42-months after the last participant was randomized, or until death, for follow-up assessment.

03

Conditions studied

  • Relapsed Peripheral T-Cell Lymphoma
  • Refractory Peripheral T-Cell Lymphoma

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants age 18 or older
  • Participants with Peripheral T cell lymphoma (PTCL) (selected subtypes) according to World Health Organization (WHO) criteria and have or are refractory to at least 1 prior systemic, cytotoxic therapy for PTCL. Participants must have received conventional therapy as a prior therapy. Cutaneous-only disease is not permitted. Participants must have documented evidence of progressive and .
  • Tumor available for central hematopathologic review
  • (ECOG) performance status of 0-2
  • Female participants who are post menopausal for at least 1 year, surgically sterile, or agree to practice 2 effective methods of through 30 days after the last dose of study drug or agree to abstain from heterosexual intercourse.
  • Male participants who agree to practice effective barrier contraception through 6 months after the last dose of alisertib or agree to abstain from heterosexual intercourse
  • Suitable venous access
  • Voluntary written consent

Exclusion criteria

Exclusion Criteria

  • Known central nervous system lymphoma
  • Systemic antineoplastic therapy, immunotherapy, agent or radiation therapy within 4 weeks of first dose of study treatment or concomitant use during study
  • Prior administration of an Aurora A kinase-targeted agent, including alisertib; or all of the 3 comparator drugs (pralatrexate, or romidepsin or gemcitabine; or known )
  • History of uncontrolled sleep apnea syndrome or other conditions that could result in excessive daytime sleepiness
  • Cardiac condition as specified in study protocol, including (LVEF) \<40%
  • Concomitant use of other medicines as specified in study protocol
  • Participants with abnormal gastric or bowel function who require continuous treatment with H2-receptor antagonists or proton pump inhibitors
  • Known active infection with (HIV), virus, or
  • stem cell transplant less than 3 months prior to enrollment
  • Participants who have undergone allogeneic stem cell or organ transplantation any time
  • Inadequate blood levels, bone marrow or other organ function as specified in study protocol
  • The participant must have recovered to National Cancer Institute (NCI CTCAE) Grade ≤ 1 toxicity, to participant's baseline status (except alopecia), or deemed irreversible from the effects of prior cancer therapy
  • Major surgery, serious infection, or infection requiring systemic antibiotic therapy within 14 days prior to the first dose of study treatment
  • Female participants who are breastfeeding or pregnant
  • Coexistent second or history of prior solid organ malignancy within previous 3 years
  • Serious medical or psychiatric illness or laboratory abnormality that could, in the investigator's opinion, potentially interfere with the completion of treatment according to the protocol
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
271 participants (actual)

Study arms

  • Experimental
    Alisertib

    Alisertib 50 mg, enteric-coated tablet formulation, orally, twice daily for 7 consecutive days (Cycle Days 1-7) in a 21-day cycle (Up to 148 Weeks).

    Drug: Alisertib

  • Active comparator
    Pralatrexate, or Romidepsin, or Gemcitabine

    Pralatrexate 30 mg/m\^2, intravenous (IV) push over 3 to 5 minutes, once weekly, for 6 weeks in 7-week cycles with concurrent vitamin B12 and folic acid supplementation. Cycles were repeated every 7-weeks provided the participant continued to benefit from and tolerate the therapy (Up to 115 Weeks), or Gemcitabine 1,000 mg/m\^2 over 30 minutes, intravenously, on Days 1, 8, and 15 of a 28-day cycle until the absence of disease progression or unacceptable toxicity (Up to 32 Weeks), or Romidepsin 14 mg/m\^2, intravenously over a 4-hour period, on Days 1, 8, and 15 of a 28-cycle. Cycles were repeated every 28 days provided the patient continued to benefit from and tolerate the therapy (Up to 30 Weeks).

    Drug: Pralatrexate · Drug: Gemcitabine · Drug: Romidepsin

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) Based on Independent Review Committee (IRC) Assessment

    ORR was defined as the percentage of participants who achieve Complete Response (CR) or Partial Response (PR) as assessed by the IRC using International Working Group (IWG) criteria. CR=Disappearance of all evidence of disease and PR=Regression of measurable disease and no new sites.

    Time frame: Every 8 weeks from date of first dose treatment; every 12 weeks after 40 week assessment; at end of treatment visit until progressive disease. Duration is approximately 3 years

  2. Progression-Free Survival (PFS) Based on IRC Assessment

    PFS was defined as the time from the date of randomization to the date of first documentation of progressive disease (PD) or death due to any cause, whichever occurred first.

    Time frame: Every 8 weeks from date of first dose treatment; every 12 weeks after 40 week assessment; at end of treatment visit until progressive disease. Duration is approximately 3 years

Secondary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from the date of randomization to the date of death. Participants without documentation of death were censored at the date last known to be alive.

    Time frame: Participants were followed for survival for 2 years from date of last participant off study treatment, or death, whichever occurs first. Contacts were every 4 months (Median follow-up 519 days in the alisertib arm and 586 days in the comparative arm)

  2. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. A SAE is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/ birth defect or is a medically important event.

    Time frame: First dose to 30 days after last dose of study drug or comparator (Up to 152 Weeks)

  3. Number of Participants With Clinically Important Abnormal Laboratory Values Reported as AEs

    Clinical laboratory tests included chemistry, hematology and urinalysis test. Clinically significant treatment-emergent laboratory abnormalities were reported by the investigator as TEAEs.

    Time frame: First dose to 30 days after last dose of study drug or comparator (Up to 152 Weeks)

  4. Number of Participants With Clinically Important Vital Sign Measurements Reported as AEs

    Vital signs included blood pressure, heart rate and temperature. Individual clinically significant changes in vital signs were reported by the investigator as TEAEs.

    Time frame: First dose to 30 days after last dose of study drug or comparator (Up to 152 Weeks)

  5. Complete Response (CR) Rate

    Complete Response (CR) rate is defined as the percentage of participants with CR as assessed by the IRC using IWG criteria (2007 Cheson). CR= Disappearance of all evidence of disease.

    Time frame: At the end of every 8 weeks from date of first dose treatment; every 12 weeks after 40 week assessment; at end of treatment visit until PD (approximately 3 years)

  6. Time to Disease Progression (TTP)

    Time to Progression (TTP) was defined as the time from the date of randomization to the date of first documentation of PD/relapse.

    Time frame: At the end of every 8 weeks from date of first dose treatment; every 12 weeks after 40 week assessment; at end of treatment visit until progressive disease. Duration is approximately 3 years

  7. Duration of Response (DOR)

    DOR was defined as the time from the date of first documentation of a PR or better to the date of first documentation of progressive disease (PD)/relapse for responders as assessed by the IRC using IWG criteria. Responders without documentation of PD/relapse were censored at the date of last response assessment that was stable disease (SD) or better.

    Time frame: At the end of every 8 weeks from date of first dose treatment; every 12 weeks after 40 week assessment; at end of treatment visit until progressive disease. Duration is approximately 3 years

  8. Time to Response

    Time to Response is defined as the time from the date of randomization to the date of first documentation of PR or better.

    Time frame: At the end of every 8 weeks from date of first dose treatment; every 12 weeks after 40 week assessment; at end of treatment visit until progressive disease. Duration is approximately 3 years

  9. Time to Subsequent Antineoplastic Therapy

    Time to subsequent antineoplastic therapy was defined as the time from randomization to the first date of subsequent antineoplastic therapy (excluding transplant). Participants without subsequent antineoplastic therapy were censored at the date of death or last known to be alive.

    Time frame: From date of last study drug to date of subsequent antineoplastic therapy, if required; approximately 3 years

  10. Plasma Concentration-time Data to Contribute to Future Population Pharmacokinetics (PK) Analysis

    Time frame: Cycle 1, Days 1 and 7; Cycle 2, Day 8; Cycle 3, Day 8; Cycle 4, Day 8. Duration is approximately 4 months.

  11. Change Form Baseline in Reported Symptoms and Quality of Life (QoL) Assessment Per Functional Assessment of Cancer Therapy-Lymphoma (FACT-LYM) for Functioning and Symptoms

    The FACT-LYM includes the Functional Assessment of Cancer Therapy General Scale (FACT-G) and a 15-item lymphoma-specific subscale (LYM) over the past week. The FACT-G has 27 items that incorporate 4 scales including physical well-being (PWB; 7 items), social/family well-being (SWB, 7 items), emotional well-being (EWB; 6 items), and functional well-being (FWB; 7 items). The combined FACT-LYM instrument consists of a total of a 42 item questionnaire. Each question is answered on a 5- point scale of 0 (not at all) to 4 (very much) for a total possible score of 168. Higher scores indicate better well-being and a positive change from Baseline indicates improvement.

    Time frame: Baseline and End of Treatment (EOT) (Up to 152 Weeks)

07

Results

Posted Jul 31, 2018

Participant flow

Participants took part in the study at 105 investigative sites in the United States including Puerto Rico, Canada, European Union, Russian Federation, Turkey, Israel, Australia, New Zealand and Latin America from 11 June 2012 to the end of study on 18 December 2017.

Participant flow — Overall Study
MilestoneAlisertibPralatrexate, or Romidepsin, or Gemcitabine
Started138133
Safety population: received study drug137127
Completed00
Not completed138133
Withdrew: Progressive disease6553
Withdrew: Unsatisfactory therapeutic response3723
Withdrew: Adverse event1822
Withdrew: Withdrawal by participant813
Withdrew: Hematopoietic stem cell transplant39
Withdrew: Other reason15
Withdrew: Study terminated by sponsor52
Withdrew: Did not receive study drug16

Outcome measures

PrimaryOverall Response Rate (ORR) Based on Independent Review Committee (IRC) Assessment

ORR was defined as the percentage of participants who achieve Complete Response (CR) or Partial Response (PR) as assessed by the IRC using International Working Group (IWG) criteria. CR=Disappearance of all evidence of disease and PR=Regression of measurable disease and no new sites.

Time frame:
Every 8 weeks from date of first dose treatment; every 12 weeks after 40 week assessment; at end of treatment visit until progressive disease. Duration is approximately 3 years
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) Based on Independent Review Committee (IRC) Assessment
percentage of participantsAlisertibPralatrexate, or Romidepsin, or Gemcitabine
Overall Response Rate (ORR) Based on Independent Review Committee (IRC) Assessment33 (24 to 43)45 (34 to 55)
Statistical analysis
  • Alisertib vs Pralatrexate, or Romidepsin, or Gemcitabine · Cochran-Mantel-Haenszel · p = 0.038 (P-value was stratified using disease type, International Prognostic Index (IPI) Score and region as stratification factors.) · Odds ratio (or): 0.60 · 95% CI 0.33 to 1.08
PrimaryProgression-Free Survival (PFS) Based on IRC Assessment

PFS was defined as the time from the date of randomization to the date of first documentation of progressive disease (PD) or death due to any cause, whichever occurred first.

Time frame:
Every 8 weeks from date of first dose treatment; every 12 weeks after 40 week assessment; at end of treatment visit until progressive disease. Duration is approximately 3 years
Reported as:
Median · days
Progression-Free Survival (PFS) Based on IRC Assessment
daysAlisertibPralatrexate, or Romidepsin, or Gemcitabine
Progression-Free Survival (PFS) Based on IRC Assessment115 (83 to 174)104 (61 to 114)
Statistical analysis
  • Alisertib vs Pralatrexate, or Romidepsin, or Gemcitabine · Stratified Log Rank · p = 0.177 · Hazard ratio (hr): 0.87 · 95% CI 0.637 to 1.178Hazard ratio (HR) was based on a stratified Cox's proportional hazard regression model with stratification factors: disease type, IPI Score and region with treatment as a factor in the model.
SecondaryOverall Survival (OS)

OS was defined as the time from the date of randomization to the date of death. Participants without documentation of death were censored at the date last known to be alive.

Time frame:
Participants were followed for survival for 2 years from date of last participant off study treatment, or death, whichever occurs first. Contacts were every 4 months (Median follow-up 519 days in the alisertib arm and 586 days in the comparative arm)
Reported as:
Median · days
Overall Survival (OS)
daysAlisertibPralatrexate, or Romidepsin, or Gemcitabine
Overall Survival (OS)415 (263 to 514)367 (258 to 572)
Statistical analysis
  • Alisertib vs Pralatrexate, or Romidepsin, or Gemcitabine · Stratified Log-rank Test · p = 0.338 · Hazard ratio (hr): 0.98 · 95% CI 0.707 to 1.369Hazard ratio (HR) was based on a stratified Cox's proportional hazard regression model with stratification factors: disease type, IPI Score and region with treatment as a factor in the model.
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. A SAE is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/ birth defect or is a medically important event.

Time frame:
First dose to 30 days after last dose of study drug or comparator (Up to 152 Weeks)
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
participantsAlisertibPralatrexate, or Romidepsin, or Gemcitabine
TEAE136126
SAE7569
SecondaryNumber of Participants With Clinically Important Abnormal Laboratory Values Reported as AEs

Clinical laboratory tests included chemistry, hematology and urinalysis test. Clinically significant treatment-emergent laboratory abnormalities were reported by the investigator as TEAEs.

Time frame:
First dose to 30 days after last dose of study drug or comparator (Up to 152 Weeks)
Reported as:
Number · participants
Number of Participants With Clinically Important Abnormal Laboratory Values Reported as AEs
participantsAlisertibPralatrexate, or Romidepsin, or Gemcitabine
Neutrophil Count Decreased1814
White Blood Cell Count Decreased1710
Lymphocyte Count Decreased65
Monocyte Count Decreased21
Lymphocyte Count Increased10
Monocyte Count Increased10
White Blood Cell Count Increased10
Platelet Count Decreased1522
Alanine Aminotransferase Increased811
Aspartate Aminotransferase Increased511
Gamma-glutamyltransferase Increased63
Blood Bilirubin Increased21
Hepatic Enzyme Increased20
Liver Function Test Abnormal01
Transaminases Increased01
Blood Alkaline Phosphatase Increased97
Blood Lactate Dehydrogenase Increased51
Blood Creatinine Increased37
Blood Creatinine Decreased01
Blood Urea Increased10
Blood Potassium Decreased14
Blood Magnesium Decreased12
Blood Bicarbonate Decreased01
Blood Calcium Decreased01
Blood Calcium Increased10
Blood Phosphorus Decreased01
Calcium Ionised Increased10
Haemoglobin Decreased13
Haematocrit Increased12
Haematocrit Decreased10
Coagulation Factor XIII Level Decreased10
International Normalised Ratio Increased10
Blood Albumin Decreased02
Myocardial Necrosis Marker Increased10
Troponin Increased01
Blood Glucose Increased01
Immunoglobulins Increased10
Blood Uric Acid Increased10
Enterovirus Test Positive01
SecondaryNumber of Participants With Clinically Important Vital Sign Measurements Reported as AEs

Vital signs included blood pressure, heart rate and temperature. Individual clinically significant changes in vital signs were reported by the investigator as TEAEs.

Time frame:
First dose to 30 days after last dose of study drug or comparator (Up to 152 Weeks)
Reported as:
Number · participants
Number of Participants With Clinically Important Vital Sign Measurements Reported as AEs
participantsAlisertibPralatrexate, or Romidepsin, or Gemcitabine
Heart Rate Increased10
Body Temperature Increased01
Hypotension46
Orthostatic Hypotension21
Hypertension57
Pyrexia4840
SecondaryComplete Response (CR) Rate

Complete Response (CR) rate is defined as the percentage of participants with CR as assessed by the IRC using IWG criteria (2007 Cheson). CR= Disappearance of all evidence of disease.

Time frame:
At the end of every 8 weeks from date of first dose treatment; every 12 weeks after 40 week assessment; at end of treatment visit until PD (approximately 3 years)
Reported as:
Number · percentage of participants
Complete Response (CR) Rate
percentage of participantsAlisertibPralatrexate, or Romidepsin, or Gemcitabine
Complete Response (CR) Rate18 (11 to 26)27 (18 to 37)
SecondaryTime to Disease Progression (TTP)

Time to Progression (TTP) was defined as the time from the date of randomization to the date of first documentation of PD/relapse.

Time frame:
At the end of every 8 weeks from date of first dose treatment; every 12 weeks after 40 week assessment; at end of treatment visit until progressive disease. Duration is approximately 3 years
Reported as:
Median · days
Time to Disease Progression (TTP)
daysAlisertibPralatrexate, or Romidepsin, or Gemcitabine
Time to Disease Progression (TTP)162 (114 to 231)116 (101 to 227)
Statistical analysis
  • Alisertib vs Pralatrexate, or Romidepsin, or Gemcitabine · Stratified Log Rank · p = 0.362 · Hazard ratio (hr): 0.95 · 95% CI 0.679 to 1.329Hazard ratio was based on a stratified Cox's proportional hazard regression model with stratification factors: disease type, IPI Score and region with treatment as a factor in the model.
SecondaryDuration of Response (DOR)

DOR was defined as the time from the date of first documentation of a PR or better to the date of first documentation of progressive disease (PD)/relapse for responders as assessed by the IRC using IWG criteria. Responders without documentation of PD/relapse were censored at the date of last response assessment that was stable disease (SD) or better.

Time frame:
At the end of every 8 weeks from date of first dose treatment; every 12 weeks after 40 week assessment; at end of treatment visit until progressive disease. Duration is approximately 3 years
Reported as:
Median · days
Duration of Response (DOR)
daysAlisertibPralatrexate, or Romidepsin, or Gemcitabine
Duration of Response (DOR)225 (125 to NA)172 (119 to NA)
SecondaryTime to Response

Time to Response is defined as the time from the date of randomization to the date of first documentation of PR or better.

Time frame:
At the end of every 8 weeks from date of first dose treatment; every 12 weeks after 40 week assessment; at end of treatment visit until progressive disease. Duration is approximately 3 years
Reported as:
Median · days
Time to Response
daysAlisertibPralatrexate, or Romidepsin, or Gemcitabine
Time to Response62 (57 to 67)64 (60 to 71)
SecondaryTime to Subsequent Antineoplastic Therapy

Time to subsequent antineoplastic therapy was defined as the time from randomization to the first date of subsequent antineoplastic therapy (excluding transplant). Participants without subsequent antineoplastic therapy were censored at the date of death or last known to be alive.

Time frame:
From date of last study drug to date of subsequent antineoplastic therapy, if required; approximately 3 years
Reported as:
Median · days
Time to Subsequent Antineoplastic Therapy
daysAlisertibPralatrexate, or Romidepsin, or Gemcitabine
Time to Subsequent Antineoplastic Therapy336 (201 to 490)233 (144 to 429)
SecondaryPlasma Concentration-time Data to Contribute to Future Population Pharmacokinetics (PK) Analysis
Time frame:
Cycle 1, Days 1 and 7; Cycle 2, Day 8; Cycle 3, Day 8; Cycle 4, Day 8. Duration is approximately 4 months.

No measurements were reported for this outcome.

SecondaryChange Form Baseline in Reported Symptoms and Quality of Life (QoL) Assessment Per Functional Assessment of Cancer Therapy-Lymphoma (FACT-LYM) for Functioning and Symptoms

The FACT-LYM includes the Functional Assessment of Cancer Therapy General Scale (FACT-G) and a 15-item lymphoma-specific subscale (LYM) over the past week. The FACT-G has 27 items that incorporate 4 scales including physical well-being (PWB; 7 items), social/family well-being (SWB, 7 items), emotional well-being (EWB; 6 items), and functional well-being (FWB; 7 items). The combined FACT-LYM instrument consists of a total of a 42 item questionnaire. Each question is answered on a 5- point scale of 0 (not at all) to 4 (very much) for a total possible score of 168. Higher scores indicate better well-being and a positive change from Baseline indicates improvement.

Time frame:
Baseline and End of Treatment (EOT) (Up to 152 Weeks)
Reported as:
Mean · score on a scale
Change Form Baseline in Reported Symptoms and Quality of Life (QoL) Assessment Per Functional Assessment of Cancer Therapy-Lymphoma (FACT-LYM) for Functioning and Symptoms
score on a scaleAlisertibPralatrexate, or Romidepsin, or Gemcitabine
Physical Well-Being, EOT-2.4 ± 6.21-1.3 ± 5.27
Social/Family Well-Being, EOT-0.3 ± 4.500.0 ± 4.44
Emotional Well-Being, EOT-1.4 ± 4.59-0.8 ± 3.93
Functional Well-Being, EOT-2.4 ± 5.40-0.3 ± 4.79

Adverse events

Collected over First dose to 30 days after last dose of study drug or comparator (Up to 152 Weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alisertib11/137 (8%)75/137 (54.7%)134/137 (97.8%)
Gemcitabine5/29 (17.2%)18/29 (62.1%)29/29 (100%)
Pralatrexate8/76 (10.5%)46/76 (60.5%)72/76 (94.7%)
Romidepsin2/22 (9.1%)6/22 (27.3%)21/22 (95.5%)
Most frequent serious events
Showing 10 of 135
Most frequent serious events
EventAlisertibGemcitabinePralatrexateRomidepsin
PyrexiaGeneral disorders12/1376/296/761/22
Febrile neutropeniaBlood and lymphatic system disorders24/1371/291/760/22
StomatitisGastrointestinal disorders7/1370/2911/760/22
DyspnoeaRespiratory, thoracic and mediastinal disorders2/1372/293/762/22
Peripheral T-cell lymphoma unspecifiedNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/1372/291/762/22
Atrial fibrillationCardiac disorders0/1370/291/762/22
DehydrationMetabolism and nutrition disorders1/1370/290/762/22
PneumoniaInfections and infestations9/1370/294/760/22
ThrombocytopeniaBlood and lymphatic system disorders7/1371/294/760/22
AnaemiaBlood and lymphatic system disorders7/1370/292/760/22
Most frequent other events
Showing 10 of 81
Most frequent other events
EventAlisertibGemcitabinePralatrexateRomidepsin
NauseaGastrointestinal disorders35/1377/2923/7615/22
StomatitisGastrointestinal disorders42/1370/2948/762/22
AnaemiaBlood and lymphatic system disorders74/1377/2930/766/22
NeutropeniaBlood and lymphatic system disorders66/13711/2921/767/22
DiarrhoeaGastrointestinal disorders61/1375/2918/7610/22
ThrombocytopeniaBlood and lymphatic system disorders51/13712/2929/767/22
Decreased appetiteMetabolism and nutrition disorders27/1371/2914/769/22
FatigueGeneral disorders49/13711/2914/766/22
Platelet count decreasedInvestigations16/13711/296/765/22
AlopeciaSkin and subcutaneous tissue disorders43/1370/291/760/22

Baseline characteristics

Intent-to-treat (ITT) population was defined as all participants who were randomized. The participants were analyzed according to the treatment they were randomized to receive, regardless of any errors of dosing.

Age, Continuous
Age, Continuous(years)AlisertibPralatrexate, or Romidepsin, or GemcitabineTotal
Mean61.1 ± 12.6961.4 ± 13.1661.3 ± 12.90
Sex: Female, Male
Sex: Female, Male(Participants)AlisertibPralatrexate, or Romidepsin, or GemcitabineTotal
Female464793
Male9286178
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AlisertibPralatrexate, or Romidepsin, or GemcitabineTotal
Hispanic or Latino252146
Not Hispanic or Latino105107212
Unknown or Not Reported8513
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)AlisertibPralatrexate, or Romidepsin, or GemcitabineTotal
White115114229
Black or African American8816
Asian325
Other7714
Not Reported527
Region of Enrollment
Region of Enrollment(participants)AlisertibPralatrexate, or Romidepsin, or GemcitabineTotal
Australia549
Austria224
Belgium538
Brazil121022
Bulgaria011
Canada303
Czech Republic527
Denmark325
France538
Germany617
Hungary9716
Israel033
Italy6612
Mexico314
Netherlands011
New Zealand325
Peru134
Poland7310
Portugal112
Puerto Rico011
Romania213
Russia448
Spain141125
Sweden033
Turkey101121
United Kingdom3811
United States293968
Height
Height(cm)AlisertibPralatrexate, or Romidepsin, or GemcitabineTotal
Mean170.3 ± 9.80168.2 ± 8.99169.3 ± 9.45
Weight
Weight(kg)AlisertibPralatrexate, or Romidepsin, or GemcitabineTotal
Mean76.85 ± 17.24274.63 ± 19.60175.76 ± 18.437
Body Surface Area (BSA)
Body Surface Area (BSA)(m^2)AlisertibPralatrexate, or Romidepsin, or GemcitabineTotal
Mean1.897 ± 0.24651.855 ± 0.25621.877 ± 0.2517
08

Study locations

152 sites
  • Birmingham, Alabama, United States
  • La Jolla, California, United States
  • Orlando, Florida, United States
  • Tampa, Florida, United States
  • Indianapolis, Indiana, United States
  • Iowa City, Iowa, United States
  • Boston, Massachusetts, United States
  • Detroit, Michigan, United States
  • Rochester, Minnesota, United States
  • Jefferson City, Missouri, United States
  • Saint Louis, Missouri, United States
  • Lebanon, New Hampshire, United States
  • Hackensack, New Jersey, United States
  • Buffalo, New York, United States
  • New York, New York, United States
  • Syracuse, New York, United States
  • Durham, North Carolina, United States
  • Columbus, Ohio, United States
  • Toledo, Ohio, United States
  • Charleston, South Carolina, United States
  • Houston, Texas, United States
  • Burlington, Vermont, United States
  • Seattle, Washington, United States
  • Morgantown, West Virginia, United States
  • Adelaide, Australia
  • Concord, Australia
  • Gosford, Australia
  • Hobart, Australia
  • St Leonards, Australia
  • Graz, Austria
  • Innsbruck, Austria
  • Salzburg, Austria
  • Wien, Austria
  • Minsk Didtrict, Belarus
  • Vitebsk, Belarus
  • Brugge, Belgium
  • Brussels, Belgium
  • Gent, Belgium
  • Kortrijk, Belgium
  • Turnhout, Belgium
  • Yvoir, Belgium
  • Belo Horizonte, Brazil
  • Campianas, Brazil
  • Caxias Do Sul, Brazil
  • Curitiba, Brazil
  • Goiania, Brazil
  • Porto Alegre/rs, Brazil
  • Porto Alegre, Brazil
  • Rio de Janeiro, Brazil
  • Salvador, Brazil
  • SAO Paulo - SP, Brazil
  • Sao Paulo, Brazil
  • Pleven, Bulgaria
  • Sofia, Bulgaria
  • Varna, Bulgaria
  • Ottawa, Ontario, Canada
  • Toronto, Ontario, Canada
  • Concepcion, Chile
  • Santiago, Chile
  • Praha 2, Czechia
  • Arhus C, Denmark
  • Kobenhavn O, Denmark
  • Alexandria, Egypt
  • Beni Swef, Egypt
  • Cairo, Egypt
  • Dakahlia, Egypt
  • Bordeaux, France
  • Marseille, France
  • Paris, France
  • Pessac, France
  • Pierre Benite, France
  • Tours, France
  • Berlin, Germany
  • Essen, Germany
  • Freiburg, Germany
  • Goettingen, Germany
  • Homburg/saar, Germany
  • Mainz, Germany
  • Muenchen, Germany
  • Munchen, Germany
  • ULM, Germany
  • Budapest, Hungary
  • Debrecen, Hungary
  • Kaposvar, Hungary
  • Pecs, Hungary
  • Beer-sheva, Israel
  • Haifa, Israel
  • Jerusalem, Israel
  • Petach Tikva, Israel
  • Ramat-gan, Israel
  • Tel Aviv, Israel
  • Bari, Italy
  • Bologna, Italy
  • Cagliari, Italy
  • Firenze, Italy
  • Meldola, Italy
  • Modena, Italy
  • Ravenna, Italy
  • Rimini, Italy
  • Roma, Italy

Showing the first 100 of 152 sites across 31 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • O'Connor OA, Ozcan M, Jacobsen ED, Roncero JM, Trotman J, Demeter J, Masszi T, Pereira J, Ramchandren R, Beaven A, Caballero D, Horwitz SM, Lennard A, Turgut M, Hamerschlak N, d'Amore FA, Foss F, Kim WS, Leonard JP, Zinzani PL, Chiattone CS, Hsi ED, Trumper L, Liu H, Sheldon-Waniga E, Ullmann CD, Venkatakrishnan K, Leonard EJ, Shustov AR; Lumiere Study Investigators. Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma. J Clin Oncol. 2019 Mar 10;37(8):613-623. doi: 10.1200/JCO.18.00899. Epub 2019 Feb 1. PubMed 30707661 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2012 to primary completion in Jun 2015, 36 months.

Results were first posted in Jul 2018, 3 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2011
First posted
Dec 1, 2011
StartActual
Jun 11, 2012
Primary completionActual
Jun 30, 2015
CompletionActual
Dec 18, 2017
Results first posted
Jul 31, 2018
Last update
Jul 31, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01482962
Responsible party
Sponsor
First posted
Dec 1, 2011
Start date
Jun 11, 2012
Primary completion
Jun 30, 2015
Completion
Dec 18, 2017
Results posted
Jul 31, 2018
Last update
Jul 31, 2018

Study contacts

Medical Monitor
study director · Takeda Oncology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MLN 8237

Start the discussion